Pichu Sivakamasundari, Patel Bhoomika M, Apparsundaram Subbu, Goyal Ramesh K
V Clinbio labs (P) Ltd, Sri Ramachandra University, Porur, Chennai, India.
AU-KBC, Anna University - MIT campus, Chromepet, Chennai - 44, India.
Biomark Med. 2017 Apr;11(4):377-388. doi: 10.2217/bmm-2016-0205. Epub 2017 Mar 14.
Diabetic foot ulcer (DFU) is one of the major complications of diabetes and about 1% of people with diabetes have to go for lower limb amputation. With better understanding of the pathological basis of DFU, number of biomarkers like atrial natriuretic peptides, galectin-3, and cardiac troponins for diabetic cardiomyopathy, cystatin C for diabetics nephropathy and C-reactive protein for infection and procalcitonin could aid in early and noninvasive diagnosis especially when clinical signs are misleading. Predictive role of novel biomarkers in primary prevention however, requires additional studies considering sex, age and multiple complications in DFU. The current review provides an insight about the novel and emerging biomarkers of diabetes and its complications with special reference to DFUs.
糖尿病足溃疡(DFU)是糖尿病的主要并发症之一,约1%的糖尿病患者不得不接受下肢截肢。随着对DFU病理基础的深入了解,心房利钠肽、半乳糖凝集素-3和心肌肌钙蛋白等用于诊断糖尿病性心肌病的生物标志物、胱抑素C用于诊断糖尿病肾病以及C反应蛋白用于诊断感染和降钙素原等,有助于早期无创诊断,尤其是在临床症状具有误导性时。然而,考虑到DFU中的性别、年龄和多种并发症,新型生物标志物在一级预防中的预测作用需要更多研究。本综述特别针对DFU,深入探讨了糖尿病及其并发症的新型和新兴生物标志物。